{"disease":{"id":"unresectable-hepatocellular-carcinoma-hcc","name":"unresectable hepatocellular carcinoma hcc"},"drugs":{"marketed":[],"pipeline":[],"offLabel":[],"totalMarketed":0,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT07368530","title":"Using Machine Learning to Identify Responders to TACE or HAIC for uHCC","phase":"","overall_status":"COMPLETED","enrollment_count":3000,"lead_sponsor_name":"First Affiliated Hospital, Sun Yat-Sen University","has_results":false},{"nct_id":"NCT06739317","title":"SBRT Combined with Camrelizumab and Apatinib for Conversion Therapy in Patients with Unresectable Hepatocellular Carcinoma.","phase":"PHASE2, PHASE3","overall_status":"NOT_YET_RECRUITING","enrollment_count":398,"lead_sponsor_name":"Sun Yat-sen University","has_results":false},{"nct_id":"NCT07391839","title":"MDN-001 Injection for the Treatment of Unresectable Primary Hepatocellular Carcinoma.","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":40,"lead_sponsor_name":"Suzhou Mednovo Yi Medical Technology Co., Ltd.","has_results":false},{"nct_id":"NCT07408804","title":"Comparison of Response Between Combination of Transarterial Chemoembolization and Lenvatinib Therapy Versus Lenvatinib Monotherapy in Patients With Unresectable Hepatocellular Carcinoma","phase":"NA","overall_status":"RECRUITING","enrollment_count":40,"lead_sponsor_name":"Bangladesh Medical University","has_results":false},{"nct_id":"NCT05630937","title":"Study on Safety and Efficacy of NMS-01940153E in Adult Patients With Unresectable Hepatocellular Carcinoma (HCC) Previously Treated With Systemic Therapy","phase":"PHASE1, PHASE2","overall_status":"TERMINATED","enrollment_count":31,"lead_sponsor_name":"Nerviano Medical Sciences","has_results":true},{"nct_id":"NCT02953743","title":"Pharmacokinetic Study of E7080/Lenvatinib in Chinese Patients With Unresectable Hepatocellular Carcinoma (HCC)","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":25,"lead_sponsor_name":"Eisai Co., Ltd.","has_results":false},{"nct_id":"NCT01498952","title":"MEDI-573 in Combination With SOC in Unresectable or Metastatic HCC.","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":6,"lead_sponsor_name":"MedImmune LLC","has_results":true}],"total":7},"guidelines":[],"source":"Drug Landscape verified database"}